ArticleHepatology international2022
Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice.
Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Bibliometric analysis of human microbiota-associated animal model (2005-2025).Frontiers in microbiology · 2026Pooled it
- Review
- Bile Acid Binding Resins Improve Glucagon Receptor Agonist-Mediated Weight Loss in Diet-Induced Obese Mice.Obesity (Silver Spring, Md.) · 2026Article
- Bile Acids and Type 2 Diabetes: Roles in Glucose Homeostasis and Therapeutic Opportunities.Metabolites · 2025Review
- Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases.Microorganisms · 2025Review
- Article
- Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system.PloS one · 2025Article
- The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice.International journal of molecular sciences · 2024Article
- Divergence in aerobic capacity influences hepatic and systemic metabolic adaptations to bile acid sequestrant and short-term high-fat/sucrose feeding in rats.American journal of physiology. Regulatory, integrative and comparative physiology · 2023Article
- Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2023Review
- Bile Acid Sequestrants Based on Natural and Synthetic Gels.Gels (Basel, Switzerland) · 2023Review
- Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease.Clinical science (London, England : 1979) · 2023Review
- How to calculate sample size in animal and human studies.Frontiers in medicine · 2023Review
- Bile acids and microbes in metabolic disease.World journal of gastroenterology · 2022Review
- Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels.Methods and protocols · 2022Article
- Modulation of the Bile Acid Enterohepatic Cycle by Intestinal Microbiota Alleviates Alcohol Liver Disease.Cells · 2022Article
- Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective.Therapeutic advances in gastroenterology · 2022Review
- Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundObesity, non-alcoholic fatty liver disease (NAFLD) and its more advanced form non-alcoholic steatohepatitis (NASH) are important causes of morbidity and mortality worldwide. Bile acid dysregulation is a pivotal part in their pathogenesis. The aim of this study was to evaluate the bile acid sequestrant colesevelam in a microbiome-humanized mouse model of diet-induced obesity and steatohepatitis.
methodsGerm-free C57BL/6 mice were associated with stool from patients with NASH and subjected to 20 weeks of Western diet feeding with and without colesevelam.
resultsColesevelam reduced Western diet-induced body and liver weight gain in microbiome-humanized mice compared with controls. It ameliorated Western diet-induced hepatic inflammation, steatosis, fibrosis and insulin resistance. Colesevelam increased de novo bile acid synthesis and decreased hepatic cholesterol content in microbiome-humanized mice fed a Western diet. It further induced the gene expression of the antimicrobials Reg3g and Reg3b in the distal small intestine and decreased plasma levels of LPS.
conclusionsColesevelam ameliorates Western diet-induced steatohepatitis and obesity in microbiome-humanized mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.